PubMed
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
Rosenstock et al., 2023
GLP-1 & MetabolicPhase 3A
Retatrutide
LY3437943
Retatrutide (LY3437943) is Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist in Phase III clinical trials. The TRIUMPH-4 trial (December 2025) achieved 28.7% average weight loss (71.2 lbs from a 248.5 lb baseline) at 68 weeks with 12mg — the highest weight loss efficacy recorded for any obesity medication to date. It is not FDA-approved. FDA has stated it cannot be lawfully compounded under 503A/503B.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 8
- Research grade
- A
- Experience
- 99
- Activity
- 39
Overall check-ins
Trackers & reports
Overview
About Retatrutide
Retatrutide (LY3437943) is Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist in Phase III clinical trials. The TRIUMPH-4 trial (December 2025) achieved 28.7% average weight loss (71.2 lbs from a 248.5 lb baseline) at 68 weeks with 12mg — the highest weight loss efficacy recorded for any obesity medication to date. It is not FDA-approved. FDA has stated it cannot be lawfully compounded under 503A/503B.
- Category
- GLP-1 & Metabolic
- Regulatory status
- Phase 3
- Also known as
- LY3437943
- Self-reports
- 125
Community
What 125 users report
125 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 99% · Mixed 1% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
222
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
3
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 1–2 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
5
0.1–0.2 mg
3
0.2–0.4 mg
6
0.4–0.6 mg
10
0.6–1 mg
5
1–2 mg
80
2–3 mg
35
3–5 mg
17
5+ mg
61
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 100% said they felt similar to their last entry, 0% more positive, and 0% more negative.
Overall, repeat reporters leaned similar or mixed compared to their previous entry.
Median gap between entries: 51 days · Based on 45 repeat reporters
Research
Cited research (6)
Source
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff et al., 2023
ClinicalTrials.gov
Retatrutide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
ClinicalTrials.gov
Retatrutide studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Jastreboff et al., 2023
PubMed
Retatrutide-A Game Changer in Obesity Pharmacotherapy
Katsi et al., 2025
Tools
Explore more
Explore
More ways to learn about Retatrutide from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Retatrutide?
This page summarizes 125 anonymized self-reports from PeptIQ users who track Retatrutide, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Retatrutide?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Retatrutide?
6 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Retatrutide safe to use?
This wiki does not assess safety or recommend use. Retatrutide is listed as Phase 3. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Retatrutide?
This wiki summarizes observational community reports and linked citations for Retatrutide. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for Retatrutide for study-level context — not medical advice.
What is the legal status of Retatrutide?
Retatrutide is listed in PeptIQ as Phase 3. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of Retatrutide?
Safety data quality for Retatrutide varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on Retatrutide?
This page links 6 indexed sources for Retatrutide. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.